- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Eupraxia Pharmaceuticals Misses Q1 Earnings Estimates
Biotech firm's stock falls as it reports wider-than-expected loss per share
Mar. 19, 2026 at 1:20pm
Got story updates? Submit your updates here. ›
Eupraxia Pharmaceuticals (NASDAQ:EPRX), a clinical-stage biotech company focused on autoimmune and inflammatory diseases, announced its Q1 2026 earnings results on Thursday. The company reported a loss of $0.37 per share, missing analysts' consensus estimate of a $0.16 loss per share by $0.21.
Why it matters
Eupraxia's miss on earnings expectations caused its stock price to fall, as investors reacted negatively to the wider-than-anticipated loss. The company's ability to meet financial targets is closely watched as it advances its lead therapeutic candidate through clinical trials for systemic lupus erythematosus.
The details
Eupraxia reported a net loss of $0.37 per share for the quarter, compared to the $0.16 loss per share that analysts had projected. The company's shares opened at $7.51 on the day of the earnings announcement, down from a previous close of $8.30. Eupraxia is developing a proprietary platform focused on selectively expanding regulatory T cells to treat autoimmune and inflammatory diseases.
- Eupraxia Pharmaceuticals announced its Q1 2026 earnings results on Thursday, March 19, 2026.
The players
Eupraxia Pharmaceuticals
A clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases.
The takeaway
Eupraxia's miss on Q1 earnings expectations highlights the challenges biotech firms face in meeting financial targets as they advance their drug pipelines. The company's ability to effectively manage costs and deliver on clinical milestones will be crucial as it works to bring new treatments to market.
